This retrospective study collects and evaluates the clinical experience reached in Italy on the use of bendamustine alone or combined with rituximab as treatment of patients with relapsed or refractory chronic lymphoproliferative disorders.
Study Type
OBSERVATIONAL
Enrollment
109
Gruppo Italiano Studio Linfomi
Modena, Italy
overall response rate
Time frame: within 1 month after end of treatment
grade III and IV (NCI Common Toxicity Criteria) adverse events
Time frame: within 1 month after end of treatment
prognostic factors
Time frame: within 1 month after end of treatment
progression free survival
Time frame: within 1 month after end of treatment
overall survival
Time frame: within 1 month after end of treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.